Provides next-generation sequencing diagnostics to healthcare providers. Offers polymerase chain reaction profiling and molecular genotyping services. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 49% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades 43% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 49% a year on average.
The company sells $1.3B a year; the problem isn’t sales — it’s costs running above that number.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
A loss of $245.0M against $1.3B in annual sales.
This stock swings about 3.7 times as much as the market average. Big rallies — and big drops — can both happen fast.
Over the last 12 months, executives reported 213 sells against just 23 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, TEM sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: TEM has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (46/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.